Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 1/20 | 0.47 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.45 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.45 |
| ▸ | BACE1 | P56817 | 2/20 | 0.44 |
| ▸ | NAMPT | P43490 | 3/20 | 0.43 |
| ▸ | TMPRSS2 | O15393 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 5/20 | 0.40 |
| ▸ | RAB9A | P51151 | 5/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.39 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20873115 | 0.80 | NPC1 (0.59) | NAMPTNPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL20873108 | 0.79 | GRM4 (0.56) | NAMPTTMPRSS2NPC1RAB9AKMT2A | |
| SCHEMBL20873105 | 0.78 | RAB9A (0.66) | NPC1RAB9AKMT2ATP53SMN1; SMN2 | |
| SCHEMBL22493878 | 0.78 | NPC1 (0.44) | BACE1NAMPTTMPRSS2NPC1RAB9A | |
| SCHEMBL20873126 | 0.78 | KCNK3 (0.54) | NAMPTTMPRSS2NPC1RAB9AACHE | |
| SCHEMBL20873100 | 0.76 | F2R (0.47) | F2RPRMT5WDR77NAMPTTMPRSS2 | |
| SCHEMBL20873113 | 0.76 | AHR (0.54) | PRMT5WDR77NAMPTTMPRSS2NPC1 | |
| SCHEMBL20873116 | 0.76 | NAMPT (0.45) | NAMPTTMPRSS2NPC1RAB9AKMT2A | |
| SCHEMBL22493893 | 0.74 | LMNA (0.59) | NAMPTTMPRSS2NPC1RAB9AACHE | |
| SCHEMBL22493871 | 0.74 | F2R (0.48) | F2RPRMT5WDR77BACE1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3464289-B1 | ULTRA-POTENT VINCA ALKALOIDS: ADDED MOLECULAR COMPLEXITY FURTHER DISRUPTS THE TUBULIN DIMER-DIMER INTERFACE | SCRIPPS RESEARCH INST (US) | 2021-04-21 | — | — | EP | disclosed |
| US-10975101-B2 | Ultra-potent vinca alkaloids: added molecular complexity further disrupts the tublin dimer-dimer interface | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-04-13 | — | — | US | disclosed |
| US-20200317696-A1 | ULTRA-POTENT VINA ALKALOIDS: ADDED MOLECULAR COMPLEXITY FURTHER DISRUPTS THE TUBLIN DIMER-DIMER INTERFACE | NATIONAL INSTITUTES OF HEALTH | 2020-10-08 | — | — | US | disclosed |
| EP-3464289-A1 | ULTRA-POTENT VINA ALKALOIDS: ADDED MOLECULAR COMPLEXITY FURTHER DISRUPTS THE TUBLIN DIMER-DIMER INTERFACE | The Scripps Research Institute (US) | 2019-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10975101-B2 | Ultra-potent vinca alkaloids: added molecular complexity further disrupts the tublin dimer-dimer interface | TUBA1C, TUBB2A, TUBA1A | F2R 4563/4885PRMT5 2248/4885WDR77 1186/4885 |
| US-20200317696-A1 | ULTRA-POTENT VINA ALKALOIDS: ADDED MOLECULAR COMPLEXITY FURTHER DISRUPTS THE TUBLIN DIMER-DIMER INTERFACE | TUBA1A, TUBA1C, TUBB2A | F2R 4489/4885PRMT5 2436/4885WDR77 1285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.